Amplification and/or deregulated expression of URI1 has been observed in various cancer contexts including ovarian and hepatocellular carcinoma and multiple myeloma, supporting the view that URI1 may act as a multifaceted modifier of cancer cell proliferation and survival [17–22]. Here, URI1 is linked to AL amyloidosis.